Science Pool

Evotec sample management team is responsible for the long-term storage and distribution of Evotec and partners compound collections.

In 2019, Evotec decided to invest in acoustic tubes technology in order to support future customer need and plan for potential transfer of our libraries into acoustic tubes. In parallel to this decision, Evotec sample management decided to initiate an internal project to evaluate the impact of acoustic tubes usage on compound integrity.

This poster highlights and describes the experiments performed, which substantiate and validate the use of acoustic tubes.

DOWNLOAD

•  Accelerating your drug discovery and research programs through interdisciplinary integration and expert coordination of all activities “under one roof”
• Industry-leading timelines, taking your program from the selection of an optimal clinical candidate to regulatory submission typically in less than 52 weeks
• Expert management by experienced, dedicated project managers and drug development professionals
• Seamless knowledge transfer across disciplines, maximizing the quality and efficiency of the overall development package
• Custom-designed, flexible development plans that allow for real-time adjustments and adaptability to unforeseeable scientific outcomes
• Excellence in project governance, performance review and issue escalation management

In this work, published in collaboration with Boston Children's Hospital, Evotec actively contributed to the identification of DW0254 and small molecule analogs capable of inhibiting RAC activation in acute lymphoblastic leukemia cell lines. Photoaffinity labelling mass spectrometry (PALMS) approach was successfully applied to identify PDE6D as the molecular target of DW0254. PALMS and biophysical methods were also used to identify the binding site of DW0254 in PDE6D. Our study provides evidence that PDE6D-dependent RAS trafficking with downstream activation of PI3K/AKT and RAC constitutes a novel potential therapeutic target in high risk leukemias.

DOWNLOAD

LEARN MORE

About this Webinar

In this short recording, Dr Pia Thommes, VP Anti-Infectives and Virology Therapeutic Leader discusses:

• Current challenges in Infectious Diseases drug discovery
• Human SARS-CoV-2 and other emerging viruses
• Industry relevant in vivo models
• The wider reaching consequences of the COVID pandemic

More about Dr Pia Thommes.

Pia gained her PhD in Molecular Genetics and followed this with a postdoctoral in biochemistry, focusing on DNA replication and cell cycle. She has 12 years experience in drug discovery of antivirals at GW/GSK, 4 years work in oncology on DNA Damage Response at KuDOS/ AZ. In 2012 Pia took on a role as Scientific Operations Director at Euprotec, a specialist CRO for infectious disease, this was incorporated into the Evotec family in 2014. Currently Pia is working as VP of Anti-infectives in Alderley Park and also Therapeutic Area Lead for Virology.

Hope you enjoy the webinar

Watch the Recording Now

Download this fact sheet to learn more about cytochrome P450 (CYP) induction including:

• Background information
• Assay details and protocol summary
• Data generated in the CYP induction assay

Download this fact sheet to learn more about cytochrome P450 (CYP) relative induction score (RIS) including:

• Background information for the CYP induction RIS method
• Assay details and protocol summary for the CYP induction RIS method
• Data generated in the CYP induction RIS assay

Download this fact sheet to learn more about hepatocyte stability including:

• Background information
• Assay details and protocol summary
• Data generated in the hepatocyte stability assay

Learn more about the use of transcriptomics in safety prediction including:

• the challenges in translation from animals to humans, and how human cell-based models are now being routinely used in toxicology
• how transcriptomic analysis is showing promise in enhancing safety prediction and providing additional mechanistic information
• an overview of how Cyprotex, and parent company Evotec, are offering a fully customised end-to-end in vitro transcriptomics service using the latest next generation sequencing technology (RNA-seq) and a leading bioinformatics platform
• the use of sophisticated machine learning and artificial intelligence to interpret the large and complex datasets

Deutsche Biotechnologietage is a German language only conference. The following information regarding the conference is in German for this reason.

Datum: 4. - 5. Mai 2022

Ort: CCH Congress Center, Hamburg, Deutschland 

Vortragende: Werner Lanthaler, Thomas Hanke, Sandra Lubitz, Christiane Honisch

Teilnehmer des Business Development: Daniel Gliesche, Sneha Kumar, Laurie Sarrat, Margit Wissenbach

Evotec ist Hauptsponsor der diesjährigen Deutschen Biotechnologietage und wird seine neuste Forschung vor Ort präsentieren.

Wenn Sie Interesse haben sollten sich mit uns in Hamburg zu treffen, setzen Sie sich bitte über das unten stehende Formular mit uns in Verbindung, damit wir einen Termin vereinbaren können.

Erfahren Sie mehr über die Deutsche Biotechnologietage 2022.